Author:
Abrams Paul,Kelleher Con,Staskin David,Rechberger Tomasz,Kay Richard,Martina Reynaldo,Newgreen Donald,Paireddy Asha,van Maanen Rob,Ridder Arwin
Reference17 articles.
1. Patient-reported reasons for discontinuing overactive bladder medication;Benner;BJU Int,2010
2. Efficacy and tolerability of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial;Khullar;Eur Urol,2013
3. Results of a randomized phase III trial of mirabegron in patients with overactive bladder;Nitti;J Urol,2013
4. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β3-adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder;Herschorn;Urology,2013
5. Korstanje C, Someya A, Yanai H, et al. Additive effects for increased bladder storage function with the antimuscarinic drug solifenacin and the selective β3-adrenoceptor agonist mirabegron in two rat models for in vivo bladder function. Poster 81 presented at: 43rd Meeting of the International Continence Society; August 26–30, 2013; Barcelona, Spain.
Cited by
198 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献